-+ 0.00%
-+ 0.00%
-+ 0.00%

Ensysce Biosciences Says It Fully Enrolled Part 2 Of Critical Three-Part PF614-MPAR-102 Clinical Study To Study Effect Of Food On MPAR Technology

Benzinga·06/24/2025 12:11:46
Listen to the news

~ Treatment to Evaluate Effect of Food on Overdose Protection of MPAR ~

~ Grant Funds from NIDA Accelerating Clinical Development Program ~

SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 24, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced it has fully enrolled Part 2 of the critical three-part PF614-MPAR-102 clinical study to study the effect of food on the MPAR technology.

PF614-MPAR has earned the FDA's prestigious Breakthrough Therapy designation and is uniquely engineered using Ensysce's proprietary TAAP™ (Trypsin-Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance) technologies. These platforms enable PF614-MPAR to maintain therapeutic efficacy while delivering built-in overdose protection when doses exceed prescribed amounts, whether accidentally or intentionally.

A three-year grant from the National Institute on Drug Abuse (NIDA), with second year funding recently announced1, continues to support this program through May 2027. This support will accelerate the clinical development of PF614-MPAR and could help launch a new era in pain relief with overdose protection.